Posted by Michael Wonder on 11 Sep 2023
Pharmaceutical innovativeness is highly variable, as CMS will soon find out when it does comparative effectiveness assessments
9 September 2023 - Newly approved prescription drugs are often called innovations. This is especially true in drug industry and investor circles.
And the fear expressed by these stakeholders is that legislative policies, such as the Inflation Reduction Act’s drug pricing provisions, will reduce investment in research and development, which in turn will lead to fewer innovations down the road.
